Latest news for Boule Diagnostics (OTC:BDABF) Stock

Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The firm focuses on the decentralized market segment. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. Through its subsidiaries, the Group operates in Sweden, USA, and China.

BOULE DIAGNOSTICS AB NEW by Boule Diagnostics AB

Boule Diagnostics AB

ZCAR

Zoomcar Holdings Got Notice From Nasdaq Notifying The Co Was Not In Compliance With Nasdaq Listing Rule 5450(b)(2)(c)

Macquarie analyst Chad Beynon maintains Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) with a Outperform and raises the price target from $154 to $162.

News

Price Target

Analyst Ratings

CHDN

Macquarie Maintains Outperform on Churchill Downs, Raises Price Target to $162

The tech earnings season started with disappointments for investors as shares of the <a href="https://www.benzinga.com/topic/magnificent-seven">Magnificent Seven companies</a> all declined during the trading week.
Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) reported stronger-than-expected earnings and revenue, but missed analysts&#8217; targets on <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39925881/alphabet-investors-fret-over-margin-impact-of-higher-ai-related-capex-but-fund-mana">YouTube advertising revenue</a>, leading to the worst week of the year for the Google parent company's stock.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) missed <a href="https://www.benzinga.com/news/earnings/24/07/39918390/tesla-q2-earnings-highlights-revenue-beat-eps-miss-robotaxi-update-2024-growth-rate-to-be-notably-l">quarterly earnings forecasts</a> due to thinner profit margins impacted by lower vehicle prices and restructuring charges. The electric-vehicle giant also postponed the announcement of the Robotaxi to October. Shares fell 12.3% in reaction to the earnings report on Wednesday, marking the worst one-day performance since September 2020.
The tech-heavy Nasdaq 100 index notched the second-straight week in the red for the first time since April.
Among mega-cap stocks, Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) and United Parcel Service Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) experienced the largest declines this week, followed by General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) , <a href="https://www.benzinga.com/news/24/07/39968735/gm-shares-fall-amid-earnings-report-and-sympathy-drop-with-ford">amid disappointing earnings reports</a>. The top performers among mega caps were 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) and Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), buoyed by surprising results.
Small-cap stocks outperformed once again this week, with the Russell 2000 Index marking its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39992214/russell-2000-notches-third-week-of-gains-strongest-streak-since-august-2022-small-c">third straight week of gains</a>, supported by high expectations for upcoming interest rate cuts.
On the macroeconomic front, the U.S. economy grew at an annualized pace of 2.8% in the second quarter, accelerating from the first quarter and topping expectations <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39957034/us-economy-expands-2-8-in-q2-tops-estimates-weekly-jobless-claim-fall">of 2% growth</a>.
Chart Of The Week: US GDP Growth Doubled From Q1 To Q2 2024
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="458" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26134047/image-52-1024x458.png" alt="" class="wp-image-460108" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26134047/image-52-1024x458.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26134047/image-52-300x134.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26134047/image-52-768x344.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26134047/image-52-1536x687.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/26134047/image-52.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
You might have missed…
Inflation Gauge Falls: An inflation measure followed by the Federal Reserve fell to 2.5% in June, hitting the lowest levels since February 2021 and cementing market expectations of a rate cut in September.
Yet the Fed is seeking a more &#8220;durable downward trend&#8221; before <a href="https://www.benzinga.com/top-stories/24/07/39987142/feds-favorite-inflation-gauge-keeps-falling-but-fed-wants-durable-downward-trend-economist-says">deciding to cut rates,</a> according to a Comerica Bank economist.
Alphabet Shares Drop: OpenAI plans to launch SearchGPT, a tool aimed at challenging Google&#8217;s search dominance, opening a 10,000-person waiting list to <a href="https://www.benzinga.com/news/24/07/39968522/alphabet-stock-falls-as-openai-plans-searchgpt-what-investors-need-to-know">test the new product.</a>
Mortgage Rates Ease: Mortgage rates have declined to the lowest levels since February, with the average 30-year fixed interest rate falling to 6.62%, driven by investor anticipation of future interest rate cuts. Despite this, demand <a href="https://www.benzinga.com/news/large-cap/24/07/39931211/mortgage-rates-hit-lowest-point-since-february-as-investors-anticipate-fed-rate-cuts">among homebuyers remains weak</a>.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39970069/investors-go-all-in-on-small-caps-pour-over-6-billion-into-russell-2000-etf-this-month-they-will">Investors Go All In On Small Caps, Pour Over $6 Billion Into Russell 2000 ETF This Month: They &#8216;Will Return To Larger-Cap Alternatives,&#8217; Veteran Analyst Says</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Earnings

Large Cap

Macro Economic Events

Mid Cap

Sector ETFs

Eurozone

Commodities

Small Cap

Econ #s

Economics

Federal Reserve

Markets

Tech

ETFs

GOOGL

TSLA

Tech Stocks Slide On Earnings, US Economy Flexes Muscles, Small-Cap Rally Continues: This Week In The Markets

Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) (the "Company" or "Nasdaq") today announced a secondary public offering of 41,604,207 shares of its common stock currently held by Argus Seller, LP (the "Selling Stockholder"), an affiliate of certain funds managed by Thoma Bravo, L.P. Nasdaq is not selling any shares of its common stock and will not receive any proceeds from the sale of the shares by the Selling Stockholder in the offering. &nbsp;
In addition, on July 25, 2024, Nasdaq entered into a share repurchase agreement with the Selling Stockholder conditioned on the secondary public offering, pursuant to which Nasdaq has agreed to purchase from the Selling Stockholder 1,200,000 shares of common stock, provided that the total amount of shares to be repurchased does not exceed $120 million (the "Concurrent Share Repurchase"). The Concurrent Share Repurchase is part of the Company's existing share repurchase program and offsets employee dilution. Nasdaq intends to fund the Concurrent Share Repurchase from existing cash on hand, together with borrowings under its commercial paper program. The underwriters will not receive any compensation for the shares being repurchased by Nasdaq.
At the completion of the offering and the Concurrent Share Repurchase, the Selling Stockholder is expected to hold 42,804,207 shares, representing approximately 7.4% of Nasdaq's outstanding shares, which remain subject to an existing contractual lock-up until May 1, 2025.&nbsp;&nbsp;
Goldman Sachs &amp; Co. LLC is acting as sole book-running manager for the offering.

Offerings

NDAQ

Nasdaq Announces Launch Of Secondary Offering Of 41,604,207 Shares Of Its Common Stock Currently Held By Argus Seller, LP; In Addition, Entered Into A Share Repurchase Agreement With The Selling Stockholder Conditioned On The Secondary Public Offering, Pursuant To Which Nasdaq Has Agreed To Purchase From The Selling Stockholder 1.2M Shares Of Common Stock, Provided That The Total Amount Of Shares To Be Repurchased Does Not Exceed $120M

Rail Vision Ltd. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVSN#NASDAQ">RVSN</a>), a technology company at the forefront of revolutionizing railway safety and the data-related market, announced today that on July 22, 2024, the Company received a written notice from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid price for its Ordinary Shares was below $1.00 per share for the last 30 consecutive business days.

RVSN

Rail Vision Receives Nasdaq Notification Regarding Minimum Bid Requirements

Macquarie analyst Ross Compton maintains Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Outperform and maintains $44 price target.

CART

Macquarie Maintains Outperform on Maplebear, Maintains $44 Price Target

RNAZ

TransCode Therapeutics 13G Filing Shows 3i, LP Reported A 9.9% Stake In The Co As Of July 23, 2024

REKR

Rekor Systems Files For Mixed Shelf Of Up To $350M

Hudson Acquisition I Corp. (the "Company" or "HUDA") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUDA#NASDAQ">HUDA</a>) today announced that it received a delisting notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on July 23, 2024. The Notice informs the Company of its noncompliance with Nasdaq's continued listing requirements. Unless this determination is successfully appealed, the Company's securities will be delisted from the Nasdaq Global Market.

HUDA

Hudson Acquisition I Corp. Receives Nasdaq Delisting Notice From The Listing Qualifications Department Of The Nasdaq Stock Market

Al Michaels, one of the best-known sports broadcasters of all time, has covered nine <a href="https://www.benzinga.com/topic/olympics">Olympic games in total</a>, the last one being the 2016 Summer Olympics in Brazil.
This year, Michaels will play a central role for Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) and its coverage of the Olympic Games once again, but as an artificial intelligence version of himself.
"It's a crazy thing," Michaels <a href="https://x.com/HalftimeReport/status/1806738783166988412">told</a> CNBC. 
The "daily Olympic recap" will offer a personalized experience for fans on streaming platform Peacock using the AI-generated version of Michaels
While he admits he&#8217;s not a techie, Michaels said he was willing to listen to NBC&#8217;s idea. "I was frightened and I was astonished at the same time, he adds, citing how AI is here whether people are ready or not.
"You can either resist it or you can embrace it and I've chosen the latter,&#8221; he said.
Read Also: <a href="https://www.benzinga.com/general/sports-betting/24/07/39940590/scottie-scheffler-gold-medalist-golfer-looks-to-turn-2024-pga-tour-success-into-a-2024-oly" target="_blank" rel="noreferrer noopener">Scottie Scheffler, Gold Medalist? Golfer Looks To Turn 2024 PGA Tour Success Into A 2024 Olympic Medal</a>
Google Gemini Powers Search: Technology giant Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) has teamed up with Team USA and Comcast. The company's Google is the official search AI partner for Team USA in the 2024 Summer Olympics, marking the first partnership between Google and Team USA.
"This collaboration is more than just a sponsorship; it's a powerful alliance that brings together the best of technology and sports," U.S. Olympic &amp; Paralympic Committee CEO Sarah Hirshland <a href="https://www.nbcsports.com/pressbox/press-releases/google-team-usa-and-nbcuniversal-strike-new-partnership-using-google-search-and-other-ai-powered-features-to-highlight-athlete-stories-and-enhance-nbcuniversals-coverage-of-olympic-and-paralympic-games-paris-2024">said</a>.
Google will add new ways that people can search for coverage of the Olympic Games. Comcast's NBCUniversal will also utilize Google's Search, Maps and <a href="https://benzinga.com/topic/google-gemini">Gemini for its content.</a>
NBCUniversal created "explain the games," a new overview using Google Search's AI to explain important Olympic items through the power of AI and search.
Google Gemini will also be featured during NBCUniversal's coverage with the AI assistant helping to come up with suggestions for topics.
The official sponsorship for Team USA for Google and its partnership with NBCUniversal could see the company's AI search features take center stage during coverage of the games in the USA. With several technology giants competing for dominance in the search and AI assistant spaces, the partnership could be all about brand recognition and hitting new potential users.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/07/39973454/do-summer-olympics-and-gold-medals-matter-to-the-stock-market-the-results-may-surprise-you">Do Summer Olympics (And Gold Medals) Matter To The Stock Market? The Results May Surprise You</a></li>
</ul>
Image: Shutterstock

Sports

CMCSA

GOOG

Al Michaels Gets AI Makeover, Google Gemini Goes For Gold As 2024 Summer Olympics Turns High Tech

Skechers U.S.A., Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/skx#NYSE">SKX</a>) delivered second-quarter 2024 results, with the top and bottom lines lagging the Zacks Consensus Estimate. Sales improved but earnings declined year over year. Challenges such as supply-chain disruptions, foreign currency headwinds, regulatory issues in India, and weakened consumer demand in China impacted the overall performance.
However, the company continued to focus on product innovation, emphasizing comfort technologies and strategic partnerships. Comprehensive marketing efforts, including new channels for football and basketball products, supported brand growth. Skechers remains committed to its goal of reaching $10 billion in annual sales by 2026.
Over the past year, shares of this Zacks Rank #1 (Strong Buy) company have gained 24.7% against the industry&#39;s 30.3% decline.
<div class="chart_embed">
<h3>Skechers U.S.A., Inc. Price, Consensus and EPS Surprise</h3>
<h3><img alt="Skechers U.S.A., Inc. Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/32/1721993827.png" style="height:265px; width:577px" title="" /></h3>
Skechers U.S.A., Inc. price-consensus-eps-surprise-chart | Skechers U.S.A., Inc. Quote
</div>
<h3>Q2 Highlights</h3>
Skechers posted second-quarter earnings of 91 cents per share, missing the Zacks Consensus Estimate for earnings of 94 cents. Also, the bottom line declined 7.1% from the year-earlier quarter.
SKX generated sales of $2,157.6 million, lagging the consensus estimate of $2,219 million. However, the top line grew 7.2% year over year, driven by a 6.9% rise in international sales and a 7.7% increase in domestic sales. Improvements in domestic and international sales were driven by robust DTC and Wholesale sales. On a constant-currency basis, total sales grew 8.7%. 
The company&#39;s wholesale sales increased 5.5% year over year to $1.13 billion, while DTC rose 9.2% to $1.03 billion. Our estimate for wholesale and DTC sales was pegged at $1.15 billion and $1.05 billion, respectively.
Wholesale sales increased 10.3% year over year in the Americas (&quot;AMER&quot;), and 3.9% in Europe, the Middle East &amp; Africa (EMEA), partially offset by a decrease of 2.6% in the Asia Pacific (&quot;APAC&quot;). Wholesale average selling price declined 0.8%, whereas the unit volume increased 6.4% year over year.
DTC sales growth included increases of 1.4% in domestic DTC sales and 15.2% in international DTC sales. The DTC unit volume rose 10.2% and the average selling price declined 1%. Also, growth of 4.1% in the AMER, 5.8% in the APAC and 40.6% in the EMEA aided the segment&#39;s performance.
Region-wise, sales increased 7.2% year over year to $1.10 billion in the AMER, 13.7% to $492.5 million in the EMEA and 2.2% to $564.2 million in the APAC. We expected sales from the AMER, EMEA and APAC regions to increase 8.9%, 7.5% and 11.6%, respectively, for the quarter under review.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ba/72555.jpg?v=1186442497" />
Image Source: Zacks Investment Research
<h3>Margins &amp; Costs</h3>
Gross profit increased 11.7% year over year to $1.18 billion. Also, the gross margin expanded 220 basis points (bps) to 54.9%, primarily driven by lower costs per unit due to a decline in freight costs and a favorable mix of DTC volumes. We estimated the metric to expand 70 bps to 53.4% for the quarter under review.
Total operating expenses grew 16% year over year to $977.9 million. The metric, as a percentage of sales, increased 340 bps to 45.3%. We expected total operating expenses to rise 15.5% for the quarter.
Selling expenses grew 26.1% from the year-ago period to $235.9 million. Also, general and administrative expenses jumped 13.2% to $742 million. Increased costs resulted from higher brand demand creation expenditure, along with elevated labor and facility costs, such as rent and depreciation.
<h3>Other Financial Aspects</h3>
As of Jun 30, 2024, cash and cash equivalents totaled $1.28 billion, whereas short-term investments amounted to $130.1 million.
Skechers ended the quarter with long-term borrowings of $45.7 million and shareholders&#39; equity of $4.22 billion, excluding non-controlling interests of $292.3 million. The company incurred a capital expenditure of $169.5 million in the quarter.
In the second quarter of 2024, management repurchased 0.9 million shares of its Class A common stock for $60 million. The company&#39;s board authorized a new $1-billion share repurchase program.
<h3>Store Update</h3>
As of Jun 30, 2024, SKX had 5,267 stores, including 576 domestic stores, 1,126 international locations, and 3,565 distributors, licensee and franchise stores.
In the second quarter, the company opened 25 domestic stores, 98 international stores, and 194 distributors, licensee and franchise stores. It closed 12 domestic stores, 57 international stores, and 149 distributor, licensee and franchise stores in the same period.
<h3>Outlook</h3>
For 2024, management targets sales between $8.88 billion and $8.98 billion compared with the previously mentioned $8.73 billion and $8.88 billion. It predicts earnings per share (&quot;EPS&quot;) between $4.08 and $4.18 compared with the previously stated $3.95 and $4.10. Management anticipates a capital expenditure of $325-$375 million for 2024.
For the third quarter of 2024, SKX is likely to achieve sales between $2.30 billion and $2.35 billion and EPS between $1.10 and $1.15.
<h3>Other Solid Picks</h3>
Some other top-ranked stocks in the retail space are The Gap, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gps#NYSE">GPS</a>), Abercrombie &amp; Fitch Co.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anf#NYSE">ANF</a>)&nbsp;and Stitch Fix (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfix#NASDAQ">SFIX</a>).
Gap is a premier international specialty retailer, which offers a diverse range of clothing, accessories and personal care products. It currently sports a Zacks Rank #1.
The Zacks Consensus Estimate for Gap&#39;s fiscal 2024 earnings and sales indicates growth of 22.4% and 0.2%, respectively, from fiscal 2023 reported figures. GPS has a trailing four-quarter average earnings surprise of 202.7%.
Abercrombie is a specialty retailer of premium, high-quality casual apparel. It flaunts a Zacks Rank of 1 at present. ANF delivered a 28.9% earnings surprise in the last reported quarter.
The consensus estimate for Abercrombie&#39;s fiscal 2024 earnings and sales indicates growth of 47.3% and 10.4%, respectively, from the fiscal 2023 reported levels. ANF has a trailing four-quarter average earnings surprise of 210.3%.
Stitch Fix is a leading online personal styling service. It currently has a Zacks Rank of 2 (Buy).
The Zacks Consensus Estimate for Stitch Fix&#39;s fiscal 2024 earnings indicates growth of 22.6% from the year-ago actuals. SFIX has a trailing four-quarter average earnings surprise of 14.5%.
<a href="https://www.zacks.com/stock/news/2310318/skechers-skx-q2-earnings-miss-estimates-sales-rise-y-y?cid=CS-BENZ-FT-analyst_blog|earnings_article-2310318">To read this article on Zacks.com click here.</a>

Earnings Misses

Penny Stocks

Trading Ideas

SFIX

Skechers Q2 Earnings Miss Estimates, Sales Rise Y/Y

The Zacks Electronics &ndash; Miscellaneous Products industry has been suffering from challenging macroeconomic conditions, high levels of inventories with distributors and steep interest rates. The global economic turmoil is expected to keep the semiconductor capex under check, which does not bode well for industry participants in the near term. However, players like KLA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/klac#NASDAQ">KLAC</a>), Flex (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flex#NASDAQ">FLEX</a>) and Daktronics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dakt#NASDAQ">DAKT</a>) are benefiting from higher spending on advanced technologies, including augmented reality&nbsp;and virtual reality. Continuing investments in data centers, high-performance computing and 5G end markets are the key catalysts. Fab (foundry) expansion in the United States, South Korea, Taiwan and China, as well as higher spending on memory equipment, is expected to drive growth in 2024 and beyond.
Industry Description
The Zacks Electronics &ndash; Miscellaneous Products industry includes a number of original equipment manufacturers of air-conditioning systems, green energy solutions, remote-control systems, GPS navigation, home automation systems, healthcare devices, industry/factory automation, robotics, semiconductor and optical applications, and energy management solutions. The industry is evolving on digital transformation and the growing demand for silicon across multiple markets. The increasing cost of manufacturing bodes well for equipment suppliers, while the growing demand for silicon is a positive for semiconductor companies. Apart from the United States, companies in this industry are based in Japan, Germany, the Netherlands and Switzerland. These companies either have manufacturing operations in China and South-East Asia or generate significant revenues from these regions.
3 Trends Shaping the Future of the Industry
Solid Capital Spending Drives Prospects: Technology transitions are driving product complexities, which are raising the demand for solutions provided by industry participants. Increasing investment in expanding manufacturing capacity by semiconductor companies is a key catalyst in the long run (irrespective of the near-term hiccups due to the challenging macroeconomic conditions). Since semiconductor companies are the major customers of miscellaneous electronics product manufacturers, the trend bodes well for industry participants. In addition, rising spending on advanced nodes &mdash; 7 nm, 5 nm and 3 nm processes from logic and foundry customers &mdash; favors industry participants. Notably, logic and foundry spending is anticipated to be healthy this year.
Emerging Markets of Wearables, AR &amp; VR Drive Growth: Industry participants are riding on strong demand for wearables and AR and VR-supported display systems in defense, industrial, consumer applications and healthcare end markets. The adoption of AR and VR is increasing due to the growing proliferation of the metaverse.
Challenging Macroeconomic Condition is a Headwind: Industry participants are suffering from a challenging macroeconomic condition globally, with enterprises showing reluctance in committing to multi-year deals. Persistent inflation and unfavorable forex trends do not bode well for industry participants.
Zacks Industry Rank 
The Zacks Electronics &ndash; Miscellaneous Products industry is housed within the broader Zacks Computer and Technology sector. It carries a Zacks Industry Rank #184, which places it in the bottom 26% of more than 250 Zacks industries.
The group&#39;s Zacks Industry Rank, which is the average of the Zacks Rank of all member stocks, indicates dim near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one.
The industry&#39;s positioning in the bottom 50% of the Zacks-ranked industries is a result of the negative earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are pessimistic about this group&#39;s earnings growth potential. Since Jul 31, 2023, earnings estimates for the industry for the current year have moved south by 25.5%.
Given the bearish prospects, there are only a few stocks worth watching in the industry. But before we present those stocks, let&#39;s take a look at the industry&#39;s recent stock-market performance and valuation picture.
Industry Lags S&amp;P 500, Broader Sector
The Zacks Electronics &ndash; Miscellaneous Products industry has underperformed the S&amp;P 500 and the broader Zacks Computer &amp; Technology sector in the past year.
The industry has returned 9.6% during this period compared with the S&amp;P 500 composite&#39;s growth of 19.3% and the broader sector&#39;s return of 27%.
<h3>One-Year Price Performance 
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/elcmpioperf_20240726.jpg" style="height:357px; width:620px" /></h3>
Industry&#39;s Current Valuation
On the basis of the forward 12-month P/E, which is a commonly used multiple for valuing Electronics-Miscellaneous products companies, we see that the industry is currently trading at 21.32X compared with the S&amp;P 500&#39;s 21.03X and the sector&#39;s forward-12-month P/E of 25.88X.
Over the last five years, the industry has traded as high as 22.16X and as low as 17.89X, with the median being 18.12X, as the charts below show.
<h3>Forward 12-Month Price-to-Earnings (P/E) Ratio</h3>
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/elecval_20240726.jpg" style="height:229px; width:620px" />
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/elecval2_20240726.jpg" style="height:225px; width:620px" />
Stocks to Buy Right Now
Daktronics: This Brookings, SD-based digital LED display technology and audio systems provider benefits from strong order growth.
This Zacks Rank #1 (Strong Buy) company is riding on strong demand in Live Events and International business unit orders. Daktronics shares have gained 73.5% year to date.
The Zacks Consensus Estimate DAKT&#39;s fiscal 2025 earnings has increased 34.5% to $1.13 per share over the past 30 days.
<h3>Price and Consensus: DAKT</h3>
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/dakt_20240726.jpg" style="height:359px; width:620px" />
KLA: This Zacks Rank #2 (Buy) company is benefiting from the strong performance of the wafer inspection business, owing to rising demand for advanced wafer inspection applications in leading-edge technology development.
This San Jose, CA-based company is benefiting from growing investments across multiple nodes and rising capital intensity in Foundry &amp; Logic.
The Zacks Consensus Estimate for fiscal 2025 has increased by a couple of cents to $28.19 per share over the past 30 days. KLA shares have jumped 31.3% year to date.
<h3>Price and Consensus: KLAC</h3>
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/klac_20240726.jpg" style="height:358px; width:620px" />
Flex: This Zacks Rank #2 company is gaining momentum from strong demand for next-generation mobility, including EV onboard electronics and advanced computing platforms for the software-defined vehicle, which is powering the automotive unit. Health Solutions&#39; business is bolstered by top-tier digital health/ medical device demand. Solid traction in AI-driven cloud spending is a positive factor.
Flex shares have gained 1.6% in the year-to-date period. The consensus mark for FLEX&#39;s fiscal 2025 earnings has been unchanged at $2.36 per share over the past 30 days.
<h3>Price and Consensus: FLEX 
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/flex_20240726.jpg" style="height:358px; width:620px" /></h3>
<a href="https://www.zacks.com/commentary/2310123/3-electronics-stocks-to-buy-from-a-challenging-industry?cid=CS-BENZ-FT-industry_outlook-2310123">To read this article on Zacks.com click here.</a>

DAKT

FLEX

KLAC

3 Electronics Stocks to Buy From a Challenging Industry

vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. Cadisegliatin is an oral, liver selective, glucokinase activator that has been well-tolerated in over 500 subjects to date with up to six months of treatment.

Biotech

General

VTVT

vTv Therapeutics Announces FDA Has Placed A Clinical Hold On The Cadisegliatin Clinical Program Which Includes The Ongoing CATT1 Phase 3 Trial In Type 1 Diabetes

SEEL

Seelos Therapeutics Announces Nasdaq Panel Grants The Request For An Additional Period, Will Remain Listed On Nasdaq, To Regain Compliance With Rule 5550(b)(2)

NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced it will report topline data from the Company's Phase 3 BROOKLYN clinical trial (NCT05425745) on Monday, July 29, 2024.

NAMS

NewAmsterdam Pharma Announces Topline Data From Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia On Monday, July 29, 2024

Throughout the last three months, 10 analysts have evaluated Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $62.2, a high estimate of $75.00, and a low estimate of $45.00. Surpassing the previous average price target of $60.00, the current average has increased by 3.67%.
<img src="https://www.benzinga.com/files/images/story/2024/1722024140_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Dave among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jacob Stephan</td>
<td>Lake Street</td>
<td>Announces</td>
<td>Buy</td>
<td>$53.00</td>
<td>-</td>
</tr>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Jeff Cantwell</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Buy</td>
<td>$54.00</td>
<td>-</td>
</tr>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dave. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dave compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Dave's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Dave's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DAVE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dave analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Dave</h2>
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, and finding side gigs.
<h3>Dave: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Dave displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 24.95%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Dave's net margin excels beyond industry benchmarks, reaching 46.51%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Dave's ROE excels beyond industry benchmarks, reaching 31.95%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Dave's ROA excels beyond industry benchmarks, reaching 12.93%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.6, Dave adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DAVE

A Glimpse Into The Expert Outlook On Dave Through 10 Analysts

In the latest quarter, 4 analysts provided ratings for Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Dover, presenting an average target of $205.0, a high estimate of $219.00, and a low estimate of $193.00. This upward trend is apparent, with the current average reflecting a 3.4% increase from the previous average price target of $198.25.
<img src="https://www.benzinga.com/files/images/story/2024/1722024126_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Dover by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$193.00</td>
<td>$192.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$219.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$208.00</td>
<td>$208.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dover. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dover compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Dover's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Dover's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DOV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dover analyst ratings.</a>
<h2>Get to Know Dover Better</h2>
Dover is a diversified manufacturer and solutions provider delivering equipment and components, consumable supplies, aftermarket parts, software digital solutions, and support services. It operates through five segments: engineered systems, clean energy, and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
<h3>Key Indicators: Dover's Financial Health</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Dover displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 0.72%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Dover's net margin is impressive, surpassing industry averages. With a net margin of 30.19%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Dover's ROE excels beyond industry benchmarks, reaching 12.32%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.42%, the company showcases effective utilization of assets.
Debt Management: Dover's debt-to-equity ratio surpasses industry norms, standing at 0.77. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Dover Stock

LuxUrban Hotels Inc. ("LuxUrban" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>), which secures long-term operating rights for entire hotels through Master Lease Agreements (MLA) under which it manages the hotel and rents out, on a short-term basis, rooms to business and vacation travelers, today announced the launch of a proposed follow-on public offering of shares of its common stock. The Company also intends to grant the underwriters a 45-day option to purchase up to an additional 15% of the shares of common stock sold in this offering.

LUXH

LuxUrban Hotels Launches Proposed Public Offering; No Size Or Amount Disclosed

Trading Halt: Halted at 4:01:47 p.m. ET - Trading Halt: Halt News Pending

During the last three months, 15 analysts shared their evaluations of Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Universal Health Servs, revealing an average target of $197.27, a high estimate of $256.00, and a low estimate of $162.00. Marking an increase of 9.9%, the current average surpasses the previous average price target of $179.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1722024102_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Universal Health Servs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$220.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$256.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$198.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$236.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$186.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Announces</td>
<td>Neutral</td>
<td>$198.00</td>
<td>-</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$226.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$189.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$183.00</td>
<td>$181.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Universal Health Servs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Universal Health Servs compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Universal Health Servs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Universal Health Servs's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UHS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Universal Health Servs analyst ratings.</a>
<h2>Unveiling the Story Behind Universal Health Servs</h2>
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
<h3>Understanding the Numbers: Universal Health Servs's Finances</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Universal Health Servs displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 10.85%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Universal Health Servs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.81% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Universal Health Servs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.22%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Universal Health Servs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.87%, the company showcases efficient use of assets and strong financial health.
Debt Management: Universal Health Servs's debt-to-equity ratio is below the industry average at 0.85, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Boule Diagnostics

News

Latest news for Boule Diagnostics (OTC:BDABF) Stock